Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Z8N | ISIN: US62818Q3020 | Ticker-Symbol: 2W6
NASDAQ
25.07.25 | 22:00
1,910 US-Dollar
-5,91 % -0,120
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MUSTANG BIO INC Chart 1 Jahr
5-Tage-Chart
MUSTANG BIO INC 5-Tage-Chart

Aktuelle News zur MUSTANG BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.07.Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio625OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at...
► Artikel lesen
08.07.MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy1
07.07.Mustang Bio Stock Soars 200% On FDA Orphan Drug Designation10
07.07.Dow Dips 1%; Mustang Bio Shares Spike Higher2
07.07.Mustang Bio rises after FDA orphan drug status for MB-1017
07.07.Mustang Bio-Aktie steigt stark an nach FDA-Sonderstatus für Hirntumor-Therapie18
07.07.Mustang Bio stock soars after FDA grants orphan drug designation1
MUSTANG BIO Aktie jetzt für 0€ handeln
07.07.FDA grants orphan drug status to Mustang Bio's glioma treatment8
07.07.Mustang Bio, Inc.: Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma217In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting...
► Artikel lesen
28.03.MUSTANG BIO, INC. - 10-K, Annual Report10
05.03.Mustang Bio meets Nasdaq's equity listing requirements2
05.03.Mustang Bio regains compliance with Nasdaq Capital Market requirement2
05.03.Mustang Bio, Inc.: Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement181WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq")...
► Artikel lesen
05.03.MUSTANG BIO, INC. - 8-K, Current Report-
28.02.Mustang Bio stock plunges 29% on lease termination news7
27.02.Mustang Bio exits Worcester facility, sells assets to AbbVie10
27.02.Mustang Bio verlässt Standort in Worcester und verkauft Vermögenswerte an AbbVie6
27.02.Mustang Bio, Inc.: Mustang Bio Announces Sale of Fixed Assets and Exit of Facility513WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs...
► Artikel lesen
21.02.MUSTANG BIO, INC. - 8-K, Current Report12
11.02.Mustang Bio regains compliance with Nasdaq minimum bid price requirement5
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1